Another one. Big money.
From Click2Houston, September 23:
Governor Greg Abbott joined Eli Lilly and Company executives and local leaders on Tuesday in Houston to announce the pharmaceutical giant’s plans to build a $6.5 billion manufacturing campus in the city.
Abbott was joined by Eli Lilly Chair and CEO David Ricks, state Representative Harold Dutton, Harris County Commissioner Rodney Ellis, and other local and state officials, as well as public health advocates.
KPRC 2 first reported earlier this month that documents filed with the Texas Comptroller’s Office outlined the company’s plans. The facility is expected to create 4,000 construction jobs and 615 high-wage permanent roles for engineers, scientists, and operators once complete....
....MUCH MORE
From Fierce Pharma, September 16:
Eli Lilly has revealed the location of the first of four large-scale manufacturing facilities that it plans to build in the U.S. The company has selected Goochland County, Virginia, as the site of a $5 billion plant that will produce active pharmaceutical ingredients.
The facility is part of a $27 billion investment plan that the Indianapolis drugmaker laid out nearly seven months ago during a high-profile press event in Washington, D.C., dubbed “Lilly in America.”
The company expects to break ground this year on each of the new plants, which Lilly calls “mega sites.”
Lilly's move to bolster its domestic capacity and strengthen its supply chain reflects a broader industry trend in which drugmakers have poured billions of investment dollars into the U.S. in response to the growing threat of tariffs on pharmaceutical products imported from foreign countries....
....MUCH MORE
Lilly is talking $27 billion for the four plants,
The article points out an effect of the administration's various tariff regimes that don't get highlighted that often:
...Other companies that have revealed massive investment plans in the U.S. in recent months include Roche, which has pledged to spend $50 billion, and Johnson & Johnson, which has unveiled a $55 billion plan that includes bolstering its medtech business. Meanwhile, Sanofi and Novartis have committed to spend at least $20 billion each in the U.S. by the end of the decade.Not highlighted that is except maybe by us.
As noted exiting Aug. 25's "Brace for a Second China Shock. Advanced Manufacturing Is at Risk":
One of the stated goals of the tariff regime is to encourage foreign companies to establish and/or increase their manufacturing footprint in the U.S. We have seen European companies, big pharma in particular respond to this aspect of the changing world of trade.
For their own reasons, some idiosyncratic, some policy driven, we have not seen Chinese companies react in the same way. The only recent large investment announcement that comes to mind is Chinese-owned (Haier) GE Appliances:
GE Appliances shifts more production to US as part of a $3 billion investment"AstraZeneca pledges $50bn US investment ahead of drugs tariffs"
Another One: "Amgen to expand Ohio biotech manufacturing plant"
The one that really stood out for us was "Swiss pharmaceuticals company Roche announces $50B investment in US over next 5 years" because it followed so closely on the warning from the EFPIA (also because of the 50 large, that's a lot of money, no matter who you are):
Another One: "Bristol Myers to invest $40 billion in the US over 5 years, CEO says"...April 13's "Pharma CEOs alert President von der Leyen to risk of exodus to the US" on The European Federation of Pharmaceutical Industries and Associations:
Here's who "These folks" are ...
"Sanofi to Invest at Least $20 Billion in US Through 2030"
A trend is emerging.
